Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: SANA AB

Market Cap 1.75B 184M 159M 147M 138M 257M 17.59B 263M 679M 8.48B 690M 675M 29.48B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 1.75B 184M 159M 147M 138M 257M 17.59B 263M 679M 8.48B 690M 675M 29.48B EV / Sales 2026 *
6.57x
EV / Sales 2027 * 4.52x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day+2.76%
1 week-4.04%
Current month-14.26%
1 month-5.91%
3 months-16.13%
6 months-40.00%
Current year-38.44%
1 week 12.62
Extreme 12.62
14.05
1 month 12.62
Extreme 12.62
16.05
Current year 12.62
Extreme 12.62
28.3
1 year 8.03
Extreme 8.03
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap.
12-29Sell

Chief Executive Officer

5,000 0.0036%
12-29Sell

Chief Executive Officer

5,000 0.0036%
12-29Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
+2.76%-4.04%+43.25%+39.57% 185M
+1.65%+6.42%+53.16%+109.62% 54.82B
+0.03%-1.80%+49.57%+43.94% 43.27B
+2.98%-1.00%-15.90%-19.22% 21.79B
+5.96%-7.12%-0.54%+399.74% 19.92B
+0.81%-8.38%+12.77%-33.24% 15.67B
+0.53%+2.08%+8.89%-40.13% 15.26B
+1.86%+2.14%+29.41%+180.85% 13.22B
-5.27%+3.89%+90.88%+208.02% 11.58B
-1.74%-1.05%+12.88% - 11.94B
Average +0.98%-1.32%+28.44%+98.79% 20.76B
Weighted average by Cap. +1.18%+1.15%+31.98%+97.73%

Financials

2026 *2027 *
Net sales 267M 27.98M 24.28M 22.38M 20.97M 39.19M 2.68B 40M 103M 1.29B 105M 103M 4.49B 388M 40.64M 35.27M 32.51M 30.46M 56.91M 3.89B 58.1M 150M 1.88B 153M 149M 6.52B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
11/06/26 13.05 kr +2.76% 528,497
10/06/26 12.70 kr -2.08% 276,737
09/06/26 12.97 kr +1.01% 319,524
08/06/26 12.84 kr -3.75% 598,618
05/06/26 13.34 kr -1.91% 342,781

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!